Sage Journals: Discover world-class research

Abstract

Commentators tout the societal benefits of research to conclude that people have a civic duty to participate in it. A review of several problems in research demonstrate the contrary and reveal why claims we are duty-bound to participate in research deter urgently needed efforts to tackle multiple entrenched deficiencies in it.

Get full access to this article

View all access options for this article.

References

J. L.

Probstfield and

R. L.

Frye , “Strategies for Recruitment and Retention of Participants in Clinical Trials,” JAMA 306, no. 16 (2011): 1798-1799.

Bower

et al ., “Interventions to Improve Recruitment and Retention in Clinical Trials: A Survey and Workshop to Assess Current Practice and Future Priorities,” Trials 15 (2014) 399.

Harris

, “Scientific Research Is a Moral Duty,” Journal of medical ethics 31, no. 4 (2005): 242-248.

G. O.

Schaefer ,

E. J.

Emanuel , and

Wertheimer , “The Obligation to Participate in Biomedical Research,” JAMA 302, no. 1 (2009): 67-72.

Rhodes

, “Rethinking Research Ethics,” American Journal of Bioethics 5, no. 1 (2005): 7-28.

Rennie

, “Viewing Research Participation as a Moral Obligation: In Whose Interests?: Hastings Center Report 41, no. 2 (2011): 40-47.

Kimmelman and

A. J.

London , “Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty,” PLoS Med 8, no. 3 (2011): 1001-1010.

Chalmers and

Glasziou , “Avoidable Waste in the Production and Reporting of Research Evidence,” The Lancet 374, no. 9683 (2009): 86-89.

BMJ, “Why Scientists Should Be Held to a Higher Standard of Honesty Than the Average Person,” BMJ Blogs (2016), availalbe at <http://blogs.bmj.com/bmj/2014/09/02/richard-smith-why-scientists-should-be-held-to-a-higher-standard-of-honesty-than-the-average-person/> (last visited September 15, 2017).

10.

M. R.

Macleod

et al ., “Biomedical Research: Increasing Value, Reducing Waste,” The Lancet 383, no. 9912 (2014): 101-104.

11.

K. K.

Tsilidis

et al ., “Evaluation of Excess Significance Bias in Animal Studies of Neurological Diseases,” PLoS Biol 11, no. 7 (2013): e1001609.

12.

E. S.

Sena ,

H. B.

van der Worp ,

P. M.

Bath ,

D. W.

Howells , and

M. R.

Macleod , “Publication Bias in Reports of Animal Stroke Studies Leads to Major Overstatement of Efficacy,” PLoS Biol 8, no. 7 (2010): e1000344.

13.

D. A. W.

Soergel

, “Rampant Software Errors May Undermine Scientific Results [version 2],” F1000Research 3 (2015)

14.

Eklund ,

Nichols , and

Knutsson , “Can Parametric Statistical Methods Be Trusted for fMRI Bbased Group Studies?” arXiv (2015).

15.

NIH, “Rigor and Reproducibility,” available at < https://grants.nih.gov/reproducibility/index.htm> (last visited July 25, 2017).

16.

E. M.

Bik ,

Casadevall , and

F. C.

Fang , “The Prevalence of Inappropriate Image Duplication in Biomedical Research Publications,” mBio 7, no. 3 (2016): e00809-00816

17.

A. S.

Relman and

Angell , “How the Drug Industry Distorts Medicine and Politics: America's Other Drug Problem,” The New Republic, December 16, 2002.

18.

“New Drugs and Indications in 2011. France Is Better Focused on Patients' Interests after the Mediator Scandal, but Stagnation Elsewhere,”

Prescrire International 21, no. 126 (2012): 106-110.

19.

Bleyer

, “In and Out, Good and Bad News, of Generalizability of SWOG Treatment Trial Results,” Journal of the National Cancer Institute 106, no. 3 (2014): dju027.

20.

Kennedy-Martin ,

Curtis ,

Faries ,

Robinson , and

J. A.

Johnston , “Literature Review on the Representativeness of Randomized Controlled Trial Samples and Implications for the External Validity of Trial Results,” Trials 16, no. 16 (2015): 495.

21.

J. J.

Gagne and

N. K.

Choudhry , “How Many ‘Me-Too’ Drugs Is Too Many?” JAMA 305, no. 7 (2011): 711-712.

22.

K. P.

Hill ,

J. S.

Ross ,

D. S.

Egilman , and

H. M.

Krumholz , “The ADVANTAGE Seeding Trial: A Review of Internal Documents,” Annals of Internal Medicine 149, no. 4 (2008): 251-258.

23.

M. A.

Yarborough

, “Increasing Enrollment in Drug Trials: The Need for Greater Transparency about the Social Value of Research in Recruitment Efforts,” Mayo Clinic Proceedings 88, no. 3 (2013): 442-445.

24.

A. F.

Cook and

Hoas , “Trading Places: What the Research Participant Can Tell the Investigator about Informed Consent,” Journal of Clinical Research and Bioethics 2 (2011): 221.

25.

Fiacco

et al ., “Head-to-Head Randomized Trials Are Mostly Industry Sponsored and Almost Always Favor the Industry Sponsor,” Journal of Clinical Epidemiology 68, no. 7 (2015): 811-820.

26.

Barbour

et al ., “Characterisation of Trials Where Marketing Purposes Have Been Influential in Study Design: A Descriptive Study,” Trials 17, no. 1 (2016): 31

27.

Spencer ,

Carlson , and

M. J.

Webster , “Question of Risk: Medtronic's Lost Infuse Device Study,” Star Tribune, April 10, 2016.

Why There Is No Obligation to Participate in Clinical Research

Abstract

Get full access to this article

References